Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.65 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11867151 | 1.00 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL7081151 | 0.93 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL7081152 | 0.93 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL346450 | 0.91 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL21067395 | 0.91 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL346451 | 0.91 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL16802059 | 0.91 | PTGS1 (0.60) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL11866518 | 0.90 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL11866538 | 0.90 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL800525 | 0.89 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| CN-111511406-B | Challenge test for diagnosing autism spectrum disease subtypes | 斯大利卡拉公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11364311-B2 | Method of identifying ASD phenotype 1 patients | Stalicla S.A. (CH) | 2022-06-21 | — | — | US | disclosed |
| US-11357871-B2 | Challenge test for diagnosing subtypes of ASD | Stalicla S.A. (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20220003753-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 | STALICLA SA (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877540-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ASD PHENOTYPE 1 | Stalicla S.A. (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-113166811-A | Metabolic profiling for diagnosing subtype ASD phenotype 1 in patients with idiopathic autism spectrum disorders | 斯大利卡拉公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210187127-A1 | CHALLENGE TEST FOR DIAGNOSING A SUBTYPE OF AUTISM SPECTRUM DISEASE | STALICLA SA (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3706806-A1 | CHALLENGE TEST FOR DIAGNOSING A SUBTYPE OF AUTISM SPECTRUM DISEASE | Stalicla S.A. (CH) | 2020-09-16 | — | — | EP | disclosed |
| US-20190274334-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190134230-A1 | CHALLENGE TEST FOR DIAGNOSING SUBTYPES OF ASD | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20190134229-A1 | METHOD OF IDENTIFYING ASD PHENOTYPE 1 PATIENTS | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-3479845-A1 | CHALLENGE TEST FOR DIAGNOSING SUBTYPE OF AUTISM SPECTRUM DISEASE | Stalicla S.A. (CH) | 2019-05-08 | — | — | EP | disclosed |
| EP-3442352-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017181062-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2017-10-19 | — | — | WO | disclosed |
| US-8847000-B2 | Composition for alkylation and method for detoxifying a harmful compound by using the composition | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20100286424-A1 | METHOD OF DETOXIFYING A HARMFUL COMPOUND | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20090326313-A1 | Composition for the Alkylation and a Method For Detoxifying a Harmful Compound by Using The Composition | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-3984569-A | Cosmetic compositions for treating the hair containing S-substituted derivatives of glutathione | L'OREAL (FR) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286424-A1 | METHOD OF DETOXIFYING A HARMFUL COMPOUND | SCLY, AS3MT, GSTA2 | PTGS1 3107/4885GSTK1 46/4885GLO1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.